Abstract: In a system and method for transporting wind turbine tower sections on a shipping vessel a pair of support members is secured to a first wind turbine tower section generally at opposite ends of the first tower section. Another pair of support members is secured to a second wind turbine tower section generally at opposite ends of the second tower section. A pair of elongate mounting members is secured on a support surface of the shipping vessel in spaced relationship with each other. One of the support members of the first tower section and one of the support members of the second tower section are secured to one of the elongate mounting members. The other one of the support members of the first tower section and the other one of the support members of the second tower section are secured to the other one of the elongate mounting members.

Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine.

Abstract: The invention relates to the use of eszopiclone for the treatment of low-level, chronic pain and fatigue associated with pain.

Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine.

Abstract: The invention relates to the use of eszopiclone for the treatment of low-level, chronic pain and fatigue associated with pain.

Abstract: The invention relates to the use of eszopiclone for the treatment of low-level, chronic pain and fatigue associated with pain.

Abstract: The invention relates to the use of eszopiclone for the treatment of low-level, chronic pain and fatigue associated with pain.

Abstract: A method of preparing a halophthalic acid is disclosed which comprises the steps of contacting in a liquid phase reaction mixture at least one halogen-substituted ortho-xylene with oxygen and acetic acid at a temperature in a range between about 120° C. and about 220° C. in the presence of a catalyst system yielding a product mixture comprising less than 10 percent halogen-substituted ortho-xylene starting material, a halophthalic acid product, and less than about 10,000 ppm halobenzoic acid and less than about 1000 ppm halophthalide by-products based on a total amount of halophthalic acid present in the product mixture. In addition methods for the preparation of halophthalic anhydride, and recovery of high purity acetic acid from an aqueous acetic acid stream comprising HCl, which is generated during the preparation of the halophthalic acid are also disclosed.

Abstract: In a system and method for transporting wind turbine tower sections on a shipping vessel a pair of support members is secured to a first wind turbine tower section generally at opposite ends of the first tower section. Another pair of support members is secured to a second wind turbine tower section generally at opposite ends of the second tower section. A pair of elongate mounting members is secured on a support surface of the shipping vessel in spaced relationship with each other. One of the support members of the first tower section and one of the support members of the second tower section are secured to one of the elongate mounting members. The other one of the support members of the first tower section and the other one of the support members of the second tower section are secured to the other one of the elongate mounting members.

Abstract: A method of preparing a halophthalic acid is disclosed which comprises the steps of contacting in a liquid phase reaction mixture at least one halogen-substituted ortho-xylene with oxygen and acetic acid at a temperature in a range between about 120° C. and about 220° C. in the presence of a catalyst system yielding a product mixture comprising less than 10 percent halogen-substituted ortho-xylene starting material, a halophthalic acid product, and less than about 10,000 ppm halobenzoic acid and less than about 1000 ppm halophthalide by-products based on a total amount of halophthalic acid present in the product mixture. In addition methods for the preparation of halophthalic anhydride, and recovery of high purity acetic acid from an aqueous acetic acid stream comprising HCl, which is generated during the preparation of the halophthalic acid are also disclosed.

Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is an antidepressant. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is O-desmethylvenlafaxine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

Abstract: The invention relates to the use of eszopiclone for the treatment of symptoms accompanying perimenopause or menopause.

Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

Abstract: A method of preparing a halophthalic acid is disclosed which comprises the steps of contacting in a liquid phase reaction mixture at least one halogen-substituted ortho-xylene with oxygen and acetic acid at a temperature in a range between about 120° C. and about 220° C. in the presence of a catalyst system yielding a product mixture comprising less than 10 percent halogen-substituted ortho-xylene starting material, a halophthalic acid product, and less than about 10,000 ppm halobenzoic acid and less than about 1000 ppm halophthalide by-products based on a total amount of halophthalic acid present in the product mixture. In addition methods for the preparation of halophthalic anhydride, and recovery of high purity acetic acid from an aqueous acetic acid stream comprising HCl, which is generated during the preparation of the halophthalic acid are also disclosed.

Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine.

Abstract: A transportation system for a wind turbine rotor blade is provided. The transportation system includes a root fixture adapted to receive the root end of the wind turbine rotor blade, and a tip end fixture adapted to receive a tip end of the wind turbine rotor blade. The root fixture and the tip end fixture are provided as separate transportable units.

Abstract: A light-emitting textile structure, which in particular is useful for medical purposes, comprises a flat support (2) and a plurality of light-emitting elements (4) fixed thereto. Each light-emitting element comprises a light-supplying optical fiber (6), to each optical fiber (6) there being associated exactly one light-emitting element (4), which comprises at least one output zone formed by a local curvature of the optical fiber. The local curvature is selected in such a way that a lateral exit of light from the optical fiber occurs due to the absence of total reflection.

Abstract: A light-emitting textile structure, which in particular is useful for medical purposes, comprises a flat support (2) and a plurality of light-emitting elements (4) fixed thereto. Each light-emitting element comprises a light-supplying optical fiber (6), to each optical fiber (6) there being associated exactly one light-emitting element (4), which comprises at least one output zone formed by a local curvature of the optical fiber. The local curvature is selected in such a way that a lateral exit of light from the optical fiber occurs due to the absence of total reflection.